Creative Bios

  The recognition and advancement of precision oncology are heavily attributed  to cancer genomics that can provide cancer molecular information, allowing researchers to tailor treatments and improve the outcome for a spectrum of cancer and other indications. To realize the promise of precision oncology, researchers take efforts to identify and discover relevant biomarkers using genomic profilin g , either for functional, diagnostic, predictive, or prognostic purposes.   The FDA's approval of two companion diagnostics  (CDx)—the Guardant360 CDx assay and the FoundationOne Liquid CDx test in 2020 led the testing of multi-gene mutations and biomarker profiling to a new level. Prior to the approval of these two companion diagnostics that involve a combination of liquid biopsy and next-generation sequencing (NGS) technology, researchers ha d been stuck with the low meaningful mutation frequency and the difficulty in finding biospecimens with specific mutations.   Tu...

  Cancer is a condition characterized by uncontrollable cell growth or reproduction in a specific part of the body, which will ultimately invade surrounding tissues and metastasize to distant sites. Most of the time, cancer has been advanced and possibly spread throughout the body by the time it's diagnosed. Therefore, cancer diagnosis and treatment is a competition against time, for which efforts have been made to find informative biomarkers, such as mutated nucleic acids, secreted proteins, and tumor cells, that can indicate cancer at the relatively early stage.   Researchers at the Concordia University recently published a study in the journal Biosensors and Bioelectronics , which introduced a new liquid biopsy approach using lab-on-a-chip  technology, aiming at detecting cancer prior to the forming of a tumor.   M icrofluidic Chip to  Capture Cancer Biomarkers   Th is liquid biopsy method is developed on the basis of a microfluidic chip targeting extrac...